• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors Are Reacting To Genmab (CPSE:GMAB) DARZALEX Q3 Sales Report

    Simply Wall St·10/23/2026 11:38:54
    Listen to the news
    • Genmab reported that Johnson & Johnson recorded third quarter 2026 net trade sales of DARZALEX of US$4.239b, including US$2.528b from the U.S. and US$1.711b from the rest of the world.
    • This DARZALEX update gives investors a fresh read on a major royalty contributor for Genmab and a key indicator of current demand for its antibody portfolio.
    • We will now look at how Genmab's investment narrative is affected by third quarter DARZALEX sales reported at US$4.239b worldwide.

    Scan how Genmab's DARZALEX royalty story compares with other potential healthcare compounders by reviewing our curated list of 126 healthcare AI stocks.

    Genmab Investment Narrative Recap

    To own Genmab, an investor needs to believe the DARZALEX royalty stream can fund a shift toward Genmab generated oncology products while the late stage pipeline moves through approvals. The latest US$4.239b in quarterly DARZALEX sales reinforces that recurring base. It supports the idea that higher R&D and future amortization tied to Rina S and petosemtamab can be absorbed, rather than forcing sharp cost cuts.

    The key near term swing factor remains clinical and commercial execution for EPKINLY, Rina S and petosemtamab, not quarterly DARZALEX noise. The biggest current risk is that rising drug pricing pressure, heavier competition in oncology and sizeable non cash amortization leave earnings growth and margins below what is needed to justify the current P/E.

    The DARZALEX update directly connects to earlier commentary that royalty income is a high margin earnings base. With worldwide DARZALEX net trade sales above US$4.2b in both Q2 and Q3 2026, Genmab continues to benefit from a large partner driven product that helps fund its broader antibody portfolio. That steadier line item matters when one off items have already hit reported profit.

    Earlier disclosures highlighted raised 2026 revenue guidance to US$4.3b to US$4.5b supported by this royalty stream. In that context, the fresh sales number is relevant because it underpins the capacity to keep expanding Phase 3 programs, carry debt that is less well covered by operating cash flow and work through lower current net margins while still pushing toward the late stage pipeline catalysts investors are watching.

    What Analysts Are Baking Into The Genmab Story

    Analysts currently sketch a Genmab path that leans heavily on steady antibody demand and meaningful earnings expansion over the next few years. Their models point to revenue growth of 18.8% per year for three years, alongside an improvement in profit margins from 19.1% today to 25.5% in that same time frame. That margin shift matters for you because it influences how much of every incremental DARZALEX linked dollar and each new product sale potentially drops through to the bottom line.

    On the earnings side, the consensus view calls for profit to reach US$1.8b by 2029, compared with US$788.0m today. That is an increase of about 2.3x from current earnings if the pipeline converts and operating costs stay within the ranges analysts are using. Forecasts are far from uniform, with expectations stretching from US$1.2b up to US$3.0b. This spread indicates there is real disagreement over how EPKINLY, Rina S and petosemtamab will translate into profit once large scale launches are underway.

    Valuation work built on those inputs assumes Genmab would be generating US$6.9b of revenue and US$1.8b of earnings in 2029, with the stock trading on a P/E of 15.3x in that year compared with 29.5x today. Analysts also assume the share count declines by roughly 3.03% a year over the next three years, so part of the earnings per share story comes from a shrinking share base rather than only from higher profit. A discount rate of just over 6% is used to translate those future cash flows back to a present value in the Simply Wall St work.

    On today’s prices, the consensus target sits at DKK2,775.93 against a current share price of DKK2,598.0, a gap of 6.4%. That relatively small spread signals that, on average, analysts see Genmab as broadly in line with their models. For a holder, that means the market is already assigning value to both DARZALEX royalties and the late stage oncology portfolio, so any change in conviction around those earnings paths can shift the story quickly.

    Genmab's narrative projects US$6.9b revenue and US$1.8b earnings by 2029. This requires 18.8% yearly revenue growth and an earnings increase of about 2.3x from US$788.0m today.

    Uncover why Genmab's fair value indicates a 5% potential upside to its current price, which could narrow quickly.

    CPSE:GMAB 1-Year Stock Price Chart
    CPSE:GMAB 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate Genmab story puts a single catalyst front and center. Bullish analysts focus on how fast earnings could scale if proprietary oncology drugs ramp as planned, with some modeling revenue of US$9.0b and profit of US$3.0b by 2029. Those projections were set before this DARZALEX sales update, so you may see forecasts shift.

    Explore 5 other Genmab fair value estimates, including one that suggests potential upside of up to 103% from the current price!

    The Verdict Is Yours

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more Genmab sized investment ideas?

    If the Genmab story has you thinking about how to balance quality, risk and income across your portfolio, it can help to line it up against a wider set of opportunities using the Simply Wall St Screener.